Vicapsys Life Sciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
September 10, 2021 at 12:05 am IST
Share
Vicapsys Life Sciences, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced net loss was USD 231,615 compared to USD 248,067 a year ago. Basic loss per share was USD 0.01 compared to USD 0.03 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago. For the half year, net loss was USD 596,074 compared to USD 690,724 a year ago. Basic loss per share was USD 0.03 compared to USD 0.06 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago.
Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Companyâs product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
VICAPSYS LIFE SCIENCES, INC. 
